Patient characteristics
| . | Placebo, n = 28 . | Maribavir dose groups . | ||
|---|---|---|---|---|
| 100 mg twice daily, n = 28 . | 400 mg once daily, n = 28 . | 400 mg twice daily, n = 27 . | ||
| Age, y [median (range)] | 43 (22-61) | 46 (19-59) | 48 (22-64) | 51 (19-62) |
| Sex, no. (%) | ||||
| Men | 15 (54) | 17 (61) | 18 (64) | 10 (37) |
| Women | 13 (46) | 11 (39) | 10 (36) | 17 (63) |
| Underlying disease, no. (%) | ||||
| Acute leukemia | 14 (50) | 16 (57) | 16 (57) | 16 (59) |
| Lymphoma | 3 (11) | 1 (4) | 5 (18) | 3 (11) |
| Myelodysplastic syndrome | 4 (14) | 2 (7) | 2 (7) | 2 (7) |
| Chronic myelogenous leukemia | 3 (11) | 4 (14) | 2 (7) | 2 (7) |
| Chronic lymphocytic leukemia | 2 (7) | 1 (4) | 1 (4) | 1 (4) |
| Aplastic anemia | 2 (7) | 3 (11) | 1 (4) | 0 (0) |
| Other | 0 (0) | 1 (4) | 1 (4) | 3 (11) |
| Donor type, no. (%) | ||||
| Related | 15 (54) | 16 (57) | 14 (50) | 14 (52) |
| Unrelated | 13 (46) | 12 (43) | 14 (50) | 13 (48) |
| Stem cell source, no. (%) | ||||
| Peripheral blood | 23 (82) | 21 (75) | 24 (86) | 21 (78) |
| Bone marrow | 2 (7) | 6 (21) | 2 (7) | 3 (11) |
| Cord blood | 3 (11) | 1 (4) | 2 (7) | 3 (11) |
| Conditioning regimen, no. (%) | ||||
| Myeloablative | 20 (71) | 22 (79) | 17 (61) | 19 (70) |
| Nonmyeloablative | 8 (29) | 6 (21) | 11 (39) | 8 (30) |
| Donor CMV serostatus, no. (%) | ||||
| Positive | 11 (39) | 16 (57) | 17 (61) | 14 (52) |
| Negative | 17 (61) | 12 (43) | 11 (39) | 13 (48) |
| Median time from transplantation to randomization, d (range) | 27 (17-32) | 28 (17-32) | 24 (14-30) | 27 (16-33) |
| . | Placebo, n = 28 . | Maribavir dose groups . | ||
|---|---|---|---|---|
| 100 mg twice daily, n = 28 . | 400 mg once daily, n = 28 . | 400 mg twice daily, n = 27 . | ||
| Age, y [median (range)] | 43 (22-61) | 46 (19-59) | 48 (22-64) | 51 (19-62) |
| Sex, no. (%) | ||||
| Men | 15 (54) | 17 (61) | 18 (64) | 10 (37) |
| Women | 13 (46) | 11 (39) | 10 (36) | 17 (63) |
| Underlying disease, no. (%) | ||||
| Acute leukemia | 14 (50) | 16 (57) | 16 (57) | 16 (59) |
| Lymphoma | 3 (11) | 1 (4) | 5 (18) | 3 (11) |
| Myelodysplastic syndrome | 4 (14) | 2 (7) | 2 (7) | 2 (7) |
| Chronic myelogenous leukemia | 3 (11) | 4 (14) | 2 (7) | 2 (7) |
| Chronic lymphocytic leukemia | 2 (7) | 1 (4) | 1 (4) | 1 (4) |
| Aplastic anemia | 2 (7) | 3 (11) | 1 (4) | 0 (0) |
| Other | 0 (0) | 1 (4) | 1 (4) | 3 (11) |
| Donor type, no. (%) | ||||
| Related | 15 (54) | 16 (57) | 14 (50) | 14 (52) |
| Unrelated | 13 (46) | 12 (43) | 14 (50) | 13 (48) |
| Stem cell source, no. (%) | ||||
| Peripheral blood | 23 (82) | 21 (75) | 24 (86) | 21 (78) |
| Bone marrow | 2 (7) | 6 (21) | 2 (7) | 3 (11) |
| Cord blood | 3 (11) | 1 (4) | 2 (7) | 3 (11) |
| Conditioning regimen, no. (%) | ||||
| Myeloablative | 20 (71) | 22 (79) | 17 (61) | 19 (70) |
| Nonmyeloablative | 8 (29) | 6 (21) | 11 (39) | 8 (30) |
| Donor CMV serostatus, no. (%) | ||||
| Positive | 11 (39) | 16 (57) | 17 (61) | 14 (52) |
| Negative | 17 (61) | 12 (43) | 11 (39) | 13 (48) |
| Median time from transplantation to randomization, d (range) | 27 (17-32) | 28 (17-32) | 24 (14-30) | 27 (16-33) |